EyePoint Pharmaceuticals, Inc.
EYPT
$11.84
-$0.20-1.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -78.19% | 111.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -78.19% | 111.02% | |||
| Cost of Revenue | -6.44% | 35.15% | |||
| Gross Profit | -45.23% | -7.35% | |||
| SG&A Expenses | -13.24% | 9.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.82% | 28.97% | |||
| Operating Income | -27.42% | -7.95% | |||
| Income Before Tax | -31.28% | -9.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.49% | -9.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.49% | -9.17% | |||
| EBIT | -27.42% | -7.95% | |||
| EBITDA | -27.61% | -7.97% | |||
| EPS Basic | -31.18% | -1.01% | |||
| Normalized Basic EPS | -30.97% | -1.25% | |||
| EPS Diluted | -31.18% | -1.01% | |||
| Normalized Diluted EPS | -30.97% | -1.25% | |||
| Average Basic Shares Outstanding | 0.23% | 8.07% | |||
| Average Diluted Shares Outstanding | 0.23% | 8.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||